PHGN Photogen Technologies (MM)

Photogen Technologies Names Richard T. Dean, Ph.D. to its Board of Directors SAN DIEGO, Nov. 7 /PRNewswire-FirstCall/ -- Photogen Technologies, Inc. announced today that it has appointed Richard T. Dean, Ph.D. to its Board of Directors. Dr. Dean's appointment was effective as of October 27, 2003. "Dick brings with him excellent operating experience in the radiopharmaceutical and diagnostic imaging fields which will be very beneficial to Photogen as we proceed with the marketing and sale of our new imaging product, Imagent(R)," said Taffy J. Williams, Ph.D., President and Chief Executive Officer of Photogen. Dr. Williams said, "The Board and I are looking forward to working with Dr. Dean as Photogen continues to develop and market its platform of imaging products." Dr. Dean is currently an investment advisor to NeoMed Fund, Oslo, Norway, a healthcare focused fund, and previously served as Head of Strategic Business Development, Diagnostic and Radiopharmaceuticals, Schering AG, Berlin, Germany. He also has extensive experience in the field of diagnostic imaging, having previously held executive positions with Mallinckrodt Medical and Centocor, a subsidiary of Johnson & Johnson. Dr Dean founded Diatide Inc., a company focused on discovering and developing novel radiopharmaceutical products, which he took public and ultimately sold to Schering AG. Dr. Dean received his Ph.D. in Chemistry from the University of California, Berkeley. About Photogen Photogen Technologies, Inc. develops and markets a platform of innovative imaging products. The company recently acquired the medical imaging business of Alliance Pharmaceutical Corp., led by Imagent(R) (perflexane lipid microspheres), an FDA approved ultrasound imaging product. Photogen's development programs use a versatile iodinated nanoparticulate formulation that shows promise as a subcutaneous, intravenous or intra-arterial agent for both cardiovascular imaging and lymphography (the diagnosis of cancer metastasizing to lymph nodes). PH-50, which is entering Phase 1 clinical studies, has potential benefits when used with conventional or computed tomography (CT) angiography to address the need for early detection of coronary artery disease, cancer and other diseases affecting the body's arteries and organs. N1177, which is entering Phase 2 clinical studies, has potential applications for the diagnosis and staging of cancers such as breast, prostate, lung, melanoma, uterine, cervical, and head and neck cancer. Statements in this release that are not strictly historical are "forward-looking" statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks that may cause Photogen's actual results in the future to differ materially from expected results. These risks and uncertainties include the ability of the company to: obtain necessary financing to support its development and commercialization programs, maintain and defend intellectual property protection for its proprietary products, avoid infringing intellectual property rights of third parties, successfully market its approved product, develop additional products and obtain regulatory approval for their use, and manufacture or obtain supplies of drug product. These and other risks are described and qualified in their entirety by cautionary language and risk factors set forth in the company's filings from time to time with the Securities and Exchange Commission. Brooks Boveroux, CFO Photogen Technologies, Inc. (858) 410-5601 Brian Ritchie EURO RSCG Life NRP (212) 845-4269 DATASOURCE: Photogen Technologies, Inc. CONTACT: Brooks Boveroux, CFO of Photogen Technologies, Inc., +1-858-410-5601; or Brian Ritchie EURO RSCG Life NRP, +1-212-845-4269, for Photogen Technologies, Inc.

Copyright